{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:11:29Z","timestamp":1772781089303,"version":"3.50.1"},"reference-count":31,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/03007995.2025.2536612","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:38:03Z","timestamp":1753432683000},"page":"1227-1238","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Economic burden and treatment patterns among patients with mantle cell lymphoma in the United States: a retrospective study of administrative claims data"],"prefix":"10.1080","volume":"41","author":[{"given":"Mahek","family":"Garg","sequence":"first","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambika","family":"Satija","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Sarpong","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Meade","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Ryland","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.760041"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190383"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020291"},{"key":"e_1_3_6_7_1","unstructured":"Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for B-cell lymphomas V.2.2024. \u00a9 National Comprehensive Cancer Network Inc; 2024 [cited 2024 Jun 03]. Available from: NCCN.org"},{"key":"e_1_3_6_8_1","unstructured":"United States Food and Drug Administration. Prescribing information - CALQUENCE\u00ae (acalabrutinib); 2022 [cited 2024 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210259s009lbl.pdf"},{"key":"e_1_3_6_9_1","unstructured":"United States Food and Drug Administration. Prescribing information - BRUKINSA\u00ae. (zanubrutinib); 2019 [cited 2024 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213217s010lbl.pdf"},{"key":"e_1_3_6_10_1","unstructured":"AbbVie. Update on IMBRUVICA\u00ae (ibrutinib) U.S. accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications; 2023 [cited 2024 Jan 22]. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm"},{"key":"e_1_3_6_11_1","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma; 2023 [cited 2024 Jan 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V20.5.202354"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158036"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509320"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2559"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13721"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1957806"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_349509"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2216458"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005715"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.06.005"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.06.006"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129677"},{"key":"e_1_3_6_25_1","unstructured":"United States Food and Drug Administration. Prescribing information - IMBRUVICA\u00ae (ibrutinib); 2023 [cited 2024 Jan 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205552s040 210563s017lbl.pdf"},{"key":"e_1_3_6_26_1","unstructured":"National Cancer Institute. CAR T-cell therapy approved by FDA for mantle cell lymphoma; 2020 [cited 2024 Jan 22]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-brexucabtagene-mantle-cell-lymphoma"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1950529"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011152"},{"key":"e_1_3_6_30_1","unstructured":"Rosa K. FDA approves pirtobrutinib for relapsed or refractory mantle cell lymphoma; 2023 [cited 2024 Jan 22]. Available from: https:\/\/www.onclive.com\/view\/fda-approves-pirtobrutinib-for-relapsed-or-refractory-mantle-cell-lymphoma"},{"key":"e_1_3_6_31_1","unstructured":"Pharmaceutical Technology. Nemtabrutinib by Merck for mantle cell lymphoma: likelihood of approval; 2023 [cited 2024 Jan 22]. Available from: https:\/\/www.pharmaceutical-technology.com\/data-insights\/nemtabrutinib-merck-mantle-cell-lymphoma-likelihood-of-approval\/"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2025.2536612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:51:16Z","timestamp":1762343476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2025.2536612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/03007995.2025.2536612"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2025.2536612","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}